SCHEMBL27010446

SCHEMBL27010446

COC1(CC(C)C)CN(Cc2ccc(S(=O)(=O)N3CCOCC3)cc2)C1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
TSHR P16473 2/20 0.53
KDM4E B2RXH2 2/20 0.46
USP2 O75604 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
POLB P06746 2/20 0.45
MAPK1 P28482 3/20 0.45
GAA P10253 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26620516 0.88 TSHR (0.56) ALDH1A1TSHRKDM4EUSP2HSD17B10
SCHEMBL27010441 0.88 L3MBTL1 (0.49) ALDH1A1TSHRLMNASMN1; SMN2POLB
SCHEMBL24316262 0.86 TSHR (0.54) ALDH1A1TSHRKDM4EUSP2HSD17B10
SCHEMBL24317303 0.85 ALDH1A1 (0.62) ALDH1A1TSHRKDM4EUSP2LMNA
SCHEMBL27010323 0.84 ALDH1A1 (0.57) ALDH1A1TSHRKDM4EUSP2HSD17B10
SCHEMBL27010443 0.84 ALDH1A1 (0.60) ALDH1A1TSHRKDM4EUSP2LMNA
SCHEMBL24316062 0.83 TSHR (0.58) ALDH1A1TSHRKDM4EUSP2HSD17B10
SCHEMBL27010324 0.83 ALDH1A1 (0.61) ALDH1A1TSHRKDM4EUSP2LMNA
SCHEMBL27010436 0.81 PTGDR2 (0.44) ALDH1A1TSHRUSP2SMN1; SMN2POLB
SCHEMBL26620219 0.80 TSHR (0.64) ALDH1A1TSHRKDM4EUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 ALDH1A1 2267/4885TSHR 2445/4885KDM4E 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.